2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

603. Lymphoid Oncogenesis: Basic: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Immunology, Immunodeficiency, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Metabolic Disorders, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Pediatric, Young Adult, Animal Model
PAPER

3231 SWI/SNF is required for ikaros and aiolos chromatin binding and multiple myeloma survival.

Chloe C. Wells, N/A, Jonathan C. Patton2, Yusuke Yamashita, MD, PhD3, Yanyan Gu, PhD4, Sagar Lonial, MD, FACP5, Marta Chesi, PhD6, P. Leif Bergsagel, MD7, Arul M Chinnaiyan, MD, PhD8, Lanbo Xiao, PhD9, Benjamin Gabriel Barwick, PhD10
1 Emory University, Atlanta, Georgia, United States
2 Emory University, Atlanta, Georgia, United States
3 Mayo Clinic, Scottsdale, Arizona, United States
4 Emory University, Atlanta, Georgia, United States
5 Emory University, Atlanta, Georgia, United States
6 Mayo Clinic, Scottsdale, Arizona, United States
7 Mayo Clinic, Scottsdale, Arizona, United States
8 University of Michigan, Ann Arbor, Michigan, United States
9 University of Michigan, Ann Arbor, Michigan, United States
10 Emory University, Atlanta, Georgia, United States

Introduction:
Immunomodulatory drugs (IMiDs) are a backbone therapy in multiple myeloma (MM) that target the lineage transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). IKZF1 and IKZF3 drive the IRF4-MYC regulatory loop, sustaining gene expression networks central to malignant plasma cell biology. Unfortunately, most MM patients develop IMiD resistance, thus identifying alternative therapeutic strategies is necessary for improving outcomes. Components of the SWI/SNF complex, an evolutionarily conserved chromatin remodeling complex central to regulating chromatin accessibility and gene expression, have recently been identified as preferential dependencies in MM. Additionally, IKZF1 has been shown to interact with SWI/SNF components in T cells, whether this interaction is conserved in MM and contributes to driving the disease has not been explored. 

Methods:
Transcriptional and chromatin accessibility changes were measured by RNA-seq (Kapa, mRNA HyperPrep) and the Assay for Transposase Accessible Chromatin-sequencing (ATAC-seq; Illumina) in Karpas620, KMS27, OPM2, MM1S, L363, and RPMI8226 cells ± 10 μM lenalidomide (Len) for 3 days. Chromatin binding of IKZF1/3 was assessed under the same conditions using Cleavage Under Targets and Tagmentation (CUT&Tag; Epicypher). Additionally, CUT&Tag was performed 8 hours after treatment with 1 μM of the SMARCA2/4 degrader AU-15330 or 1 μM pomalidomide (Pom). H929, MM1S, KMS26, and RPMI8226 myeloma cell lines were treated in a dose matrix with varying concentrations of Pom and AU-15330; cell death was measured by Annexin V and live/dead staining via flow cytometry. Protein levels after Pom or AU-15330 treatment were measured by Western blot. Interactions between SWI/SNF components and IKZF1/3 were assessed by co-immunoprecipitation (co-IP) and proximity ligation assay (PLA) with immunofluorescent imaging.

Results:
Len induced downregulation of MYC and IRF4 gene expression programs in most cell lines tested, but only 88 regions lost chromatin accessibility as opposed to 736 regions that gained accessibility (FDR <0.01). Surprisingly, regions that gained accessibility were enriched for IKZF1 binding motifs (FDR <0.01). Consistent with this, inspection of published IKZF1 ChIP-seq data showed IKZF1-bound regions gained accessibility following Len treatment. Given IKZF1 was previously reported to interact with components of the SWI/SNF complex, we tested if these co-localize on chromatin and found 58-86% of IKZF1 and IKZF3-bound regions were also bound by the SWI/SNF catalytic subunits SMARCA2 and SMARCA4. This interaction was confirmed by Co-IP and PLA between IKZF1/3 and SMARCA2/4, indicating a physical interaction between factors. Combined targeting of IKZF1/3 with Pom and SMARCA2/4 with AU-15330 revealed a lack of synergy, suggesting mechanistic redundancy between IKZF1/3 and SWI/SNF. Finally, CUT&Tag with the SWI/SNF degrader AU-15330 showed IKZF1 and IKZF3 were depleted off chromatin, despite maintaining similar protein levels, indicating IKZF1 and IKZF3 chromatin binding is dependent on SWI/SNF. 

Discussion:
These data indicate targeting SWI/SNF disrupts IKZF1/3 chromatin binding and therefore could overcome some forms of IMiD resistance. Although identifying a therapeutic window for SWI/SNF inhibitors will be a challenge, recent studies suggest this may be possible in certain enhancer-addicted cancers such as myeloma and prostate cancer (Xiao et al. Nature 2022; He et al. Cancer Cell 2024). Indeed, systematic screens have revealed SWI/SNF components as essential in myeloma and required for IRF4 expression (de Matos Simoes et al. Nature Cancer 2023; Bolomsky et al. Cancer Cell 2024). While these data indicate IKZF1 and IKZF3 are dependent upon SWI/SNF, the full repertoire of SWI/SNF-dependent and -independent transcription factors in multiple myeloma remains to be determined. Together these findings reveal IKZF1/3 require SWI/SNF-mediated chromatin accessibility to maintain their regulatory potential and point to therapeutic strategies for targeting IMiD-resistant multiple myeloma.

Chloe C. Wells, N/A: No relevant conflicts of interest to declare.